• PDF / 169,337 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 104 Downloads / 135 Views

DOWNLOAD

REPORT

---

1 S

Cyclophosphamide/docetaxel/trastuzumab Neutropenia: case report

An approximately 67-year-old woman developed neutropenia following treatment with cyclophosphamide, docetaxel and trastuzumab for human epidermal growth factor receptor 2 (HER2) positive pure mucinous breast carcinoma. The woman, who had a mass on her left breast for 3 years, was diagnosed with HER2-positive pure mucinous breast carcinoma at the age of 59 years. After a modified radical mastectomy, she received four 21-day cycles of IV docetaxel 75 mg/m2, IV cyclophosphamide 600 mg/m2 and IV trastuzumab 8 mg/kg (loading dose) on day 1 followed by 6 mg/kg every 3 weeks to complete a full year of intravenous treatment. She then received letrozole (aromatase inhibitor endocrine therapy) for 5 years. After followingup for 2 years, she was alive without recurrence of breast carcinoma. Additionally, adverse effect of grade 2 chemotherapy-induced neutropenia was observed [outcome not stated]. Zhao X, et al. HER2-positive pure mucinous breast carcinoma: A case report and literature review. Medicine 99: e20996, No. 33, 2020. Available from: URL: http:// doi.org/10.1097/MD.0000000000020996

0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803504089

Reactions 3 Oct 2020 No. 1824